Preterm labor is defined as labor before 37 weeks' gestation.
Although it's not always possible to prevent premature birth,
physicians strive to delay delivery for at least 48 hours. The
extra time allows a doctor to arrange to transfer the woman to a
medical facility experienced in treating premature infants and
helps maximize the effectiveness of steroids used to help the fetus
to prepare for the harsh outside world.
Magnesium sulfate, nifedipine and other preterm labor
treatments, called tocolytics, are thought to work by relaxing
overactive uterine muscles and halting ongoing cervical changes
that may lead to delivery. But it's not been clear if one is better
than the others. Force of habit has dictated the use of magnesium
sulfate by many physicians in the absence of a compelling reason to
choose an alternative.
Lyell and El-Sayed and their collaborators randomly assigned 192
patients at Packard Children's or Santa Clara Valley Medical Center
who were in preterm labor to receive either magnesium sulfate,
which is an intravenous treatment, or nifedipine, an oral
treatment. They found that magnesium sulfate was more effective in
achieving the study's primary outcome--preventing delivery for 48
hours with uterine quiescence. But there were no significant
differences in the treatments' ability to delay delivery, in the
gestational age of the newborn or in the birth weight of the
infants. The researchers speculate that this seeming contradiction
could be explained if nifedipine, rather than stopping a woman's
contractions, simply renders them clinically ineffective.
However, two-thirds of the women who received magnesium sulfate
experienced mild to severe side effects such as shortness of breath
and fluid build-up in the lungs during the treatment. In contrast,
one-third of the women who received nifedipine experienced side
effects of the treatment, including headaches. Nifedipine is
commonly used to treat high blood pressure and heart disease.<
'"/>
Page: 1 2 3 4 Related medicine technology :1.
Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix
Provides Excellent Protection Against Lesions Caused by Most Common
Cancer-Causing Virus Types2.
Encouraging Clinical Activity of GSKs Novel Cancer
Immunotherapeutic Confirmed in Phase II Study in Patients with Most
Common Form of Lung Cancer3.
Blood Levels of Paliperidone Extended-Release Tablets are Not
Increased by Common Antidepressant4.
Researchers Discover a Common Variation in a Gene Segment that
Increases the Risk for Prostate Cancer5.
Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million
Annually6.
One-Third of Patients Discontinue Common Breast Cancer Therapy7.
New Study in Journal of Pediatrics Suggests Synagis (Palivizumab)
May Reduce Subsequent Recurrent Wheezing in Preterm Infants8.
Preterm Infants with Respiratory Distress Syndrome: Incidence Rates
of Death when Treated with Surfactant Replacement Therapies9.
Columbia Laboratories Reports Preliminary Findings from the Ongoing
Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%
(progesterone gel) to Prevent Preterm Birth10.
New Quality Control Systems for Every Laboratory Application11.
Immunoassay Systems - Your Laboratory Workhorse